



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

MAY 08 2002

TECH CENTER 1600/2901

CERTIFICATE OF MAILING
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT
POSTAGE AS FIRST-CLASS MAIL WITH SUFFICIENT POSTAGE IN AN
ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231, ON 23 April 2002

AGENT/ATTORNEY FOR APPLICANT

23 April 2002
DATE

#5
HKO
5-14-02

Attorney Docket No. P31824C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Granett et al.

Serial No.: 10/068,514

Group Art Unit No.: 1614

Filed: 5 February 2002

Examiner: D. Jagoe

For: Composition Comprising 5-[4-[2-(N-Methyl-N-2-
Pyridyl)Amino)Ethoxy]Benzyl]Thiazolidine-2,4-Dione

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

This paper is in response to the Office's action dated 26 March 2002. Claims 1 to 22 are pending in the application. Claims 1 to 22 are subjected to restriction requirement.

Applicants reply as follows:

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Restriction is required under 35 U.S.C. 121 and 372.

Group I. Claim(s) 1 to 8, drawn to a pharmaceutical composition.


Group II. Claim(s) 9 to 14, drawn to a process for preparing a pharmaceutical composition.

Group III. Claim(s) 15 to 22, drawn to a pre-administration compound.

Serial No.: 10/068,514
Group Art Unit No.: 1614

Applicants' elect Group II containing claims 9-14 with traverse.

Respectfully submitted,



James M. Kanagy
Attorney for Applicant
Registration No. 29,550

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5014
Facsimile (610) 270-5090
N:\UMK\PATAPPS\31824\CI\restrict.doc